How amenable is type 2 diabetes treatment for precision diabetology? A meta-regression of glycaemic control data from 174 randomised trials

被引:3
作者
Kuss, Oliver [1 ,2 ,3 ]
Opitz, Marie Elisabeth [4 ]
Brandstetter, Lea Verena [4 ]
Schlesinger, Sabrina [1 ,3 ]
Roden, Michael [3 ,5 ,6 ,7 ]
Hoyer, Annika [8 ]
机构
[1] Heinrich Heine Univ Dusseldorf, Inst Biometr & Epidemiol, German Diabet Ctr, Leibniz Inst Diabet Res, Dusseldorf, Germany
[2] Heinrich Heine Univ Dusseldorf, Fac Med, Ctr Hlth & Soc, Dusseldorf, Germany
[3] German Ctr Diabet Res, Partner Dusseldorf, Neuherberg, Germany
[4] Ludwig Maximilians Univ Munchen, Dept Stat, Munich, Germany
[5] Heinrich Heine Univ Dusseldorf, Inst Clin Diabetol, German Diabet Ctr, Leibniz Ctr Diabet Res, Dusseldorf, Germany
[6] Heinrich Heine Univ Dusseldorf, Med Fac, Dept Endocrinol & Diabetol, Dusseldorf, Germany
[7] Heinrich Heine Univ Dusseldorf, Univ Hosp Dusseldorf, Dusseldorf, Germany
[8] Bielefeld Univ, Med Sch EWL, Biostat & Med Biometry, Bielefeld, Germany
关键词
Dipeptidyl peptidase-4 inhibitors; Glucagon-like peptide 1; HbA(1c); Meta-regression; Precision medicine; Sodium-glucose transporter 2 inhibitors; Type 2 diabetes mellitus; METAANALYSIS; MEDICINE;
D O I
10.1007/s00125-023-05951-2
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims/hypothesis There are two prerequisites for the precision medicine approach to be beneficial for treated individuals. First, there must be treatment heterogeneity; second, in the case of treatment heterogeneity, we need to detect clinical predictors to identify people who would benefit from one treatment more than from others. There is an established meta-regression approach to assess these two prerequisites that relies on measuring the variability of a clinical outcome after treatment in placebo-controlled randomised trials. Our aim was to apply this approach to the treatment of type 2 diabetes. Methods We performed a meta-regression analysis using information from 174 placebo-controlled randomised trials with 178 placebo and 272 verum (i.e. active treatment) arms including 86,940 participants with respect to the variability of glycaemic control as assessed by HbA(1c) after treatment and its potential predictors. Results The adjusted difference in log(SD) values between the verum and placebo arms was 0.037 (95% CI: 0.004, 0.069). That is, we found a small increase in the variability of HbA(1c) values after treatment in the verum arms. In addition, one potentially relevant predictor for explaining this increase, drug class, was observed, and GLP-1 receptor agonists yielded the largest differences in log(SD) values. Conclusions/interpretation The potential of the precision medicine approach in the treatment of type 2 diabetes is modest at best, at least with regard to an improvement in glycaemic control. Our finding of a larger variability after treatment with GLP-1 receptor agonists in individuals with poor glycaemic control should be replicated and/or validated with other clinical outcomes and with different study designs. Data availability Two datasets (one for the log[SD] and one for the baseline-corrected log[SD]) to reproduce the analyses from this paper are available on https://zenodo.org/record/7956635.
引用
收藏
页码:1622 / 1632
页数:11
相关论文
共 29 条
  • [1] Exercise training response heterogeneity: statistical insights
    Atkinson, Greg
    Williamson, Philip
    Batterham, Alan M.
    [J]. DIABETOLOGIA, 2018, 61 (02) : 496 - 497
  • [2] Is HbA1c a valid surrogate for mortality in type 2 diabetes? Evidence from a meta-analysis of randomized trials
    Baechle, Christina
    Scherler, Wiebke
    Lang, Alexander
    Filla, Tim
    Kuss, Oliver
    [J]. ACTA DIABETOLOGICA, 2022, 59 (10) : 1257 - 1263
  • [3] Chung WK, 2020, DIABETOLOGIA, V63, P1671, DOI [10.1007/s00125-020-05181-w, 10.2337/dci20-0022]
  • [4] Shattuck lecture - Medical and societal consequences of the human genome project
    Collins, FS
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (01) : 28 - 37
  • [5] Precision Medicine in Type 2 Diabetes: Using Individualized Prediction Models to Optimize Selection of Treatment
    Dennis, John M.
    [J]. DIABETES, 2020, 69 (10) : 2075 - 2085
  • [6] A roadmap to achieve pharmacological precision medicine in diabetes
    Florez, Jose C.
    Pearson, Ewan R.
    [J]. DIABETOLOGIA, 2022, 65 (11) : 1830 - 1838
  • [7] The magnitude and heterogeneity of antidepressant response in depression: A meta-analysis of over 45,000 patients
    Guo, Xin
    McCutcheon, Robert A.
    Pillinger, Toby
    Mizuno, Yuya
    Natesan, Sridhar
    Brown, Kirsten
    Howes, Oliver
    [J]. JOURNAL OF AFFECTIVE DISORDERS, 2020, 276 : 991 - 1000
  • [8] Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1
    Hammoud, Rola
    Drucker, Daniel J.
    [J]. NATURE REVIEWS ENDOCRINOLOGY, 2023, 19 (04) : 201 - 216
  • [9] A novel diabetes typology: towards precision diabetology from pathogenesis to treatment
    Herder, Christian
    Roden, Michael
    [J]. DIABETOLOGIA, 2022, 65 (11) : 1770 - 1781
  • [10] The Role of Incretins on Insulin Function and Glucose Homeostasis
    Holst, Jens Juul
    Gasbjerg, Laerke Smidt
    Rosenkilde, Mette Marie
    [J]. ENDOCRINOLOGY, 2021, 162 (07)